CADTH: Canadian Agency for Drugs and Technologies in Health

Prevention of Plantar Ulcers in People with Diabetic Peripheral Neuropathy using Pressure-Sensing Shoe Insoles

June 1, 2017

The SurroSense Rx system is a set of pressure-sensing shoe insoles that connect wirelessly to a proprietary smartwatch and is intended for people with diabetes who have mild to moderate sensory loss associated with diabetic peripheral neuropathy, or nerve damage.

By providing real-time alerts about plantar pressure distributions, or the area of pressure between the foot and the surface supporting it, users of the SurroSense Rx system can alter their activities in order to relieve unsafe pressures.

View full case study →

More Case Studies

Diabetes Can Knock You Off Your Feet

At Orpyx, we’re focussed on science & data to end preventable diabetic foot ulcers & limb loss! Did you know over half of diabetic foot ulcers will require hospitalization and 1 in 5 people will require surgical amputation. Help raise foot health awareness this month!

read more

Joslin Diabetes Center

World-renowned for deep expertise in diabetes treatment and research. Joslin Diabetes Center is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives.

read more

Alberta Diabetes Foundation

The Alberta Diabetes Foundation funds innovative research for the prevention and treatment of all forms of diabetes. We are aligned with the Alberta Diabetes Institute in Edmonton—one of the world’s finest diabetes research facilities—and progress is being made. Funding is disbursed when and where it’s needed most, moving projects along that may otherwise be stalled, facilitating measurable results.

read more

Diabetes Canada

Diabetes Canada leads the fight against diabetes by helping those affected by diabetes live healthy lives, preventing the onset and consequences of diabetes, and discovering a cure.

read more

American Diabetes Association

ADA funds research to prevent, cure and manage diabetes, deliver services to hundreds of communities, provide objective and credible information, and give voice to those denied their rights because of diabetes. Visit website.

read more

info@orpyx.com
1.855.996.7799

U.S. Patent No. 10,004,428 - June 2018
U.S. Patent No. 9,778,131 B2 - October 2017
U.S. Patent No. D740,950 S - October 2015
Australia Patent No. 2011320072 - May 2016
Japan Patent No. 6004444 - October 2016
New Zealand Patent No. 611197 - November 2015

Subscribe to our newsletter
* indicates required